Studying zilucoplan for children with generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study gives an injectable medicine called zilucoplan to children who were part of an earlier trial and could benefit from more treatment. It aims to see if zilucoplan is safe and helpful for young patients with generalized myasthenia gravis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the earlier MG0014 zilucoplan study and your doctor thinks more treatment could help you.
- You must be at least 2 years old if you live outside the US, or at least 12 if you live in the US.
- You agree to get booster shots against meningitis if your doctor recommends them.
- You cannot have antibodies to a protein called muscle-specific kinase (MuSK) which can affect how the treatment works.
- You cannot have had a previous allergic reaction to any part of zilucoplan.
- You cannot have had meningitis before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study continues treatment for children who took part in an earlier trial (MG0006) for generalized myasthenia gravis. It tests 6-week cycles of a drug called rozanolixizumab to see if it continues to work well and stay safe.
This study tests a new daily shot (zilucoplan) for children and teens with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It aims to see if the drug is safe and helps improve strength and daily functioning.
This study tests a new drug called gefurulimab in children and teens with generalized myasthenia gravis (a disease that causes muscle weakness). It looks at how safe and effective the drug is, and how it works in the body.
This study tests if an investigational drug called inebilizumab is safe and helpful for children with generalized myasthenia gravis (gMG). It is for children ages 2 to 17 who have certain antibodies or typical symptoms of gMG and are already on stable treatment.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.